Sutro Biopharma STRO Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept stro:AccruedExpensesAndOtherCurrentLiabilities.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's accrued expenses and other current liabilities?
- Sutro Biopharma (STRO) reported accrued expenses and other current liabilities of $42.97M in Q1 2026.
- How has Sutro Biopharma's accrued expenses and other current liabilities changed year-over-year?
- Sutro Biopharma's accrued expenses and other current liabilities increased by 17.5% year-over-year, from $36.57M to $42.97M.
- What is the long-term trend for Sutro Biopharma's accrued expenses and other current liabilities?
- Over 4 years (2021 to 2025), Sutro Biopharma's accrued expenses and other current liabilities has grown at a 42.4% compound annual growth rate (CAGR), from $8.4M to $34.58M.
- What does accrued expenses and other current liabilities mean?
- This represents the aggregate of short-term obligations that have been incurred but not yet invoiced or paid by the company, such as accrued compensation, professional fees, or operational expenses. It serves as a measure of the company's immediate operational commitments that will require cash settlement within the next fiscal year. Monitoring this balance helps investors assess the company's short-term liquidity pressure and the accuracy of its expense recognition.